Article Text

PDF
THU0369 The Effect of Anti-TNF Treatment in Axial Spondyloarthritis Patients Treated in Ordinary Clinical Practice – Results from Two Biorheuma Clinics in Norway
  1. G. Haugeberg1,
  2. S. Kalstad2,
  3. D. M. Soldal1,
  4. I. J. W. Hansen1,
  5. G. Bakland2
  1. 1Rheumatology, Hospital of Southern Norway Trust, Kristiansand
  2. 2Rheumatology, University of Northern Norway, Tromsø, Norway

Abstract

Background The BIORHEUMA (BIOlogic treatment of patients suffering from inflammatory RHEUMAtic disorders in Norway) project encourage participating departments to use outcome measures in daily clinical practice (ref.1). Further to obtain unselected real life data on clinical status and treatment practices in patient with inflammatory rheumatic joint disorders.

Objectives To explore in ordinary rheumatology practice the efficacy of anti-TNF treatment in axial spondyloarthritis (ax-SpA).

Methods Ax-SpA patients were recruited from two BIORHEUMA departments, one located in the southernmost part and one in the northernmost part of Norway. Both departments are monitoring their ax-SpA patients using validated outcome measures and data is primary registered for benchmarking in a clinical computer database. Data collected for structured follow up and monitoring includes demographics, disease measures (e.g. BASDAI, ASDAS, BASFI, ESR, CRP and MHAQ) and treatment registration. Anonymized data were analyzed in SPSS.

Results Among the 393 (men 271, women 122) identified patients exposed for anti-TNF treatment mean (SD) age was 46.1 (12.5) yrs, and 87% were HLAB-27+. A total of 265 had tried only one, 81 had tried 1 and 2 and 47 patients had tried 1, 2, 3 or more anti-TNF drugs. First anti-TNF treatment, sequence 1 (seq.1) was in median used for 29, seq.2 for 11 and seq.3 for 17 months. In the table mean baseline and last visit data for anti-TNF treatment is shown for seq.1, 2, and 3.

Conclusions Our real life data shows that when anti-TNF treatment is used for the first time in ax-SpA the efficacy is far better than when an anti-TNF drug is used for the second or third time.

References

  • Erik Rødevand et al. The Norwegian BIORHEUMA project – Achieving patient benchmarking and patient register in one work flow using the GoTreatIt computer software system. EULAR 2012-1882

Disclosure of Interest G. Haugeberg Shareholder of: Founder and shareholder in DiaGraphIT manufacturing GoTreatIT computer system, S. Kalstad: None Declared, D. Soldal: None Declared, I. J. Hansen: None Declared, G. Bakland: None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.